Therapeutic DLL4 binding proteins

US9469689B2 · kind B2 · utility

Assignee

• Abb Vie Inc. · US

Inventors

• Ming-Jiu Chen · Shrewsbury, US
• Chung-Ming Hsieh · Newton, US
• Jijie Gu · Shrewsbury, US
• Susan Morgan-Lappe · Chicago, US
• Yingchun Li · 安丰镇, CN

Key dates

• Filing date: Jul 14, 2015
• Grant date: Oct 18, 2016
• Expiry date: Jul 14, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.